Navigation Links
MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Date:3/13/2008

VANCOUVER and SAN DIEGO, March 13 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, reports financial results for the three and nine months ended January 31, 2008 and an update on its programs.

Jim DeMesa, M.D., President & CEO of MIGENIX stated, "With the conclusion of our third fiscal quarter and now being halfway through our fourth quarter, we are looking forward to the completion of enrollment in the Phase III Omigard registration trial for preventing catheter-related infections being conducted by our partner, Cadence Pharmaceuticals. With completion of this trial, we expect to enter into a very important time of clinical results over the next half of the year (with both Omigard and celgosivir, our Phase II hepatitis C drug candidate) followed by our potential entry into the regulatory approval process in 2009 with Omigard."

UPDATE ON DRUG DEVELOPMENT PROGRAMS

Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic peptide; prevention of catheter-related infections): A pivotal Phase III study being conducted by our development and commercialization partner Cadence Pharmaceuticals is in progress in the United States under a Special Protocol Assessment (SPA) agreement with the US FDA and in Europe. Cadence expects they will complete enrollment of the 1,850 patients planned for the trial in the second quarter of 2008, with results available in the second half of 2008. If the results of the trial are positive, Cadence expects to submit a New Drug Application ("NDA") for omiganan 1% gel in the first half of 2009. Under the terms of the agreement with Cadence, MIGENIX will receive up to US$27 million in development and commercialization milestone payments, upon the achievement of specified milestones, starting with the US and European regulatory submission process; and a double-digit royalty on net sales. MIGENIX has been and continues to be in discussions with p
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX releases CEO message #22
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
8. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
9. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... ... and expertly narrows down the product choices to a manageable shortlist of bench ... the list to models that fit best with the customer’s industry and application. ...
(Date:8/27/2015)... ... August 27, 2015 , ... Proove Biosciences, ... on the relationship of genetics and hypertension at the International Academy of ... Vancouver, British Columbia, Canada. The event, which boasts an extensive overview of the ...
(Date:8/26/2015)... Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended June 30, ... Canadian dollars and presented under International Financial Reporting ... with respect to our Oral Amp B program, ... manufacturer," said Andrew Rae , President & ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... its investment in the development and manufacture of highly valued cardiac markers used ... scientific team's extensive expertise with protein chemistry has led to the development and ...
Breaking Biology Technology:METTLER TOLEDO Updates Online Scale Selection Tool 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2
... , BASKING RIDGE, N.J., June 2 Regado Biosciences, ... antithrombotic therapeutic aptamers with active control agents, today announced ... Regado,s MAB is comprised of leaders in the fields ... These highly regarded leaders will advise the Company on ...
... NOVATO, Calif., June 2 BioMarin Pharmaceutical Inc. (Nasdaq: ... BioMarin, will present a company update at the Goldman Sachs 30th ... 9, 2009 at 9:00 a.m. ET. , , ... call via the investor section of the BioMarin website, ...
... ... ClearTrial will lead panel of adaptive trial experts offering ... clinical trials become more prevalent, their operational planning challenges often remain ... greater burden on the initial trial design, ranging from understanding the ...
Cached Biology Technology:Regado Biosciences Establishes Medical Advisory Board 2Regado Biosciences Establishes Medical Advisory Board 3BioMarin to Present at the Goldman Sachs Healthcare Conference 2ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials" 2ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials" 3
(Date:8/10/2015)... The latest 364 page report from business intelligence ... border security market . Visiongain assesses that ... Now: Border security is hard to achieve and harder ... issue you need to know about - and more importantly, ... how this will impact your company and the border security ...
(Date:8/6/2015)... TELTOW, Germany , August 6, 2015 ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted ... this new solution, unprecedented quality and efficiency is brought ... context-sensitive displays. For the first time, professionals and researchers ...
(Date:8/5/2015)... 2015 According to a new ... Software, Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, ... Forecast to 2020", published by MarketsandMarkets, defines and segments ... various segments. The global PIAM Market is estimated to ... by 2019, at a CAGR of 14.9 % from ...
Breaking Biology News(10 mins):Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... THE MOTHER FACTOR: HOW YOUR MOTHERS EMOTIONAL LEGACY IMPACTS ... will never understand the complex legacy imparted by our ... initial bond formed at birth becomes the foundation from ... evolve through adulthood. No other relationship in our ...
... of Chicago scientists has shown how two proteins locate ... protein detects and repairs damage in malignant cells that ... In a paper published in the April 24 issue ... of designing a molecule that could interfere with the ...
... the first time in Germany that healthy ovarian tissue has ... re-implanted after cancer therapy. The patient is now 32 years ... is described by Ralf Dittrich and his colleagues from Erlangen ... (Dtsch Arztebl Int 2008; 105[15]: 274-8). Anal carcinoma was ...
Cached Biology News:How your mother's emotional legacy impacts your life 2Researchers reveal structure of protein that repairs damage to cancer cells 2Researchers reveal structure of protein that repairs damage to cancer cells 3
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
... determined by Biuret. Physical form: ... 4 ) 2 SO 4 ... Affinity purified • Physical Form: ... MgCl 2 1 ZnCl ...
... PP2A, purified MW: 60kDa (A) ... glycerol, 20mM MOPS, pH 7.5, 500mM ... EGTA, 0.1mM MnCl2 1mM DTT, and ... in vitro dephosphorylation of proteins. Purification: ...
... siRNA Tracker Intracellular Localization Kit provides a ... deliver siRNA, of your design, in an ... tracking experiments. Subcellular localization and functional inhibition ... following introduction of the labeled siRNA into ...
Biology Products: